# A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome

> **NCT07695298** · PHASE4 · RECRUITING · sponsor: **Cincinnati Eye Institute, Southwest Ohio** · enrollment: 25 (estimated)

## Conditions studied

- Presumed Ocular Histoplasmosis

## Interventions

- **DRUG:** Faricimab Injection [Vabysmo]

## Key facts

- **NCT ID:** NCT07695298
- **Lead sponsor:** Cincinnati Eye Institute, Southwest Ohio
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2028-05
- **Final completion:** 2028-05
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07695298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07695298, "A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07695298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*